Lesions of the sellar region are heterogeneous and complex, including pituitary adenomas, craniopharyngiomas, Rathke cysts, germ cell tumors, pilocytic astrocytoma, hamartoma, and others. These lesions are relatively common diseases and relatively easy to manage. However, some lesions of the sellar region are very rare and difficult to manage. These rare lesions of the sellar region include McCune-Albright syndrome associated with pituitary adenomas, teratoma, multiple endocrine neoplasia type 1 (MEN1) or type 2 (MEN2A and MEN2B) associated with pituitary adenomas, pituitary carcinomas, ectopic pituitary adenomas, giant invasive pituitary adenomas, giant craniopharyngioma, Pituitary Metastasis from other tumors, Optic Glioma associated with neurofibromatosis type 1 (NF1), teratoma of the sellar region, pituitary abscess, optic nerve sheath meningiomas, and Orbital metastasis of pituitary tumors, among others.
These rare lesions of the sellar region have complex clinical features and unclear imaging features. Preoperatively, it is difficult to accurately diagnose rare lesions of the sellar region due to a lack of characteristic clinical features or diagnostic molecular markers. The management of these diseases raises major diagnostic and treatment challenges.
This Research Topic aims to provide a comprehensive overview on the recent progress of rare lesions of the sellar region, including molecular mechanisms underlining the development and progression of these diseases, the identification of potential diagnostic molecular markers, and prognostic biomarkers of response to therapies, as well as treatment options (including surgery, targeted therapies, chemotherapies, and immunotherapy), which are urgently needed to improve therapeutic results in rare lesions of the sellar region.
We welcome original research, including basic research and clinical trials, translational, as well as molecular studies, review articles, and commentary on a range of topics related to rare lesions of the sellar region.
Potential topics include, but are not limited to:
• McCune-Albright syndrome associated with pituitary adenomas;
• Teratoma of the sellar region;
• Multiple endocrine neoplasia type 1 (MEN1) or type 2 (MEN2A and MEN2B) associated with pituitary adenomas;
• Pituitary carcinomas;
• Ectopic pituitary adenomas;
• Giant invasive pituitary adenomas (Cushing’s disease, Prolactinomas, Acromegaly, TSH-secreting pituitary tumors);
• Giant craniopharyngioma;
• Pituitary Metastasis from other tumors;
• Optic Glioma associated with neurofibromatosis type 1 (NF1), optic nerve sheath meningiomas, and Orbital metastasis of pituitary tumors;
• Pituitary abscess.
Lesions of the sellar region are heterogeneous and complex, including pituitary adenomas, craniopharyngiomas, Rathke cysts, germ cell tumors, pilocytic astrocytoma, hamartoma, and others. These lesions are relatively common diseases and relatively easy to manage. However, some lesions of the sellar region are very rare and difficult to manage. These rare lesions of the sellar region include McCune-Albright syndrome associated with pituitary adenomas, teratoma, multiple endocrine neoplasia type 1 (MEN1) or type 2 (MEN2A and MEN2B) associated with pituitary adenomas, pituitary carcinomas, ectopic pituitary adenomas, giant invasive pituitary adenomas, giant craniopharyngioma, Pituitary Metastasis from other tumors, Optic Glioma associated with neurofibromatosis type 1 (NF1), teratoma of the sellar region, pituitary abscess, optic nerve sheath meningiomas, and Orbital metastasis of pituitary tumors, among others.
These rare lesions of the sellar region have complex clinical features and unclear imaging features. Preoperatively, it is difficult to accurately diagnose rare lesions of the sellar region due to a lack of characteristic clinical features or diagnostic molecular markers. The management of these diseases raises major diagnostic and treatment challenges.
This Research Topic aims to provide a comprehensive overview on the recent progress of rare lesions of the sellar region, including molecular mechanisms underlining the development and progression of these diseases, the identification of potential diagnostic molecular markers, and prognostic biomarkers of response to therapies, as well as treatment options (including surgery, targeted therapies, chemotherapies, and immunotherapy), which are urgently needed to improve therapeutic results in rare lesions of the sellar region.
We welcome original research, including basic research and clinical trials, translational, as well as molecular studies, review articles, and commentary on a range of topics related to rare lesions of the sellar region.
Potential topics include, but are not limited to:
• McCune-Albright syndrome associated with pituitary adenomas;
• Teratoma of the sellar region;
• Multiple endocrine neoplasia type 1 (MEN1) or type 2 (MEN2A and MEN2B) associated with pituitary adenomas;
• Pituitary carcinomas;
• Ectopic pituitary adenomas;
• Giant invasive pituitary adenomas (Cushing’s disease, Prolactinomas, Acromegaly, TSH-secreting pituitary tumors);
• Giant craniopharyngioma;
• Pituitary Metastasis from other tumors;
• Optic Glioma associated with neurofibromatosis type 1 (NF1), optic nerve sheath meningiomas, and Orbital metastasis of pituitary tumors;
• Pituitary abscess.
